[TheEpochTimesMay192022](Reported by Li Bei, reporter from The Epoch Times Special Department) The CCP’s epidemic prevention and control bond issuance has increased again. The entire epidemic prevention industry chain, from virus detection, isolation, vaccines to material supply, every link The benefits are enormous. In particular, the two major means of implementing the “zero policy” recently, testing and isolation, have become normalized, and there are huge economic interests behind them.
The CCP’s epidemic prevention bond issuance increases again
Since April this year, five companies in the Yangtze River Delta region have issued epidemic prevention and control bonds, with a total issuance of 1.508 billion yuan (about 220 million US dollars).
CCCC Shanghai Waterway Bureau Co., Ltd. issued the first 200 million yuan (about 29.65 million U.S. dollars) epidemic prevention and control bonds of this year’s central enterprises on May 10. The issuance period is 180 days, and the coupon rate is only 2.1%. All-time low. Of the funds raised, only 100 million yuan (about 148.2 billion U.S. dollars) will be used for epidemic prevention and control, and the other 100 million yuan will be used to supplement the company’s working capital.
The Modern Service Industry Development Group of Wenzhou City, an important export city in Zhejiang Province, also issued 100 million yuan of epidemic prevention and control bonds on April 26. The funds raised are mainly used for epidemic prevention and isolation housing construction, epidemic prevention-related material procurement, supply chain protection and epidemic situation. After the project resumes work and production, etc.
On April 15, Shanghai Jinqiao Group, a state-owned real estate development company, issued 760 million yuan (about 110 million U.S. dollars) of bonds with a coupon rate of 3.29% for a period of three years. Jinqiao Group was responsible for the procurement of materials related to epidemic prevention and control in Pudong New Area, which was the most severely affected by the epidemic during the closure and control period in Shanghai.
In addition to Jinqiao Group, another Chinese state-owned real estate development company, Shanghai Real Estate Group, also issued 2.5 billion yuan (about 370 million U.S. dollars) in bonds in March this year, of which 1.47 billion yuan (220 million U.S. dollars) was used to build four districts in Shanghai The epidemic prevention and isolation housing project.
In addition, the Export-Import Bank of China issued the market’s first “Support Shanghai Anti-epidemic Guaranteed Supply” bond at the Shanghai Clearing House on April 27, with a total issuance of 5 billion yuan (about 740 million U.S. dollars), an interest rate of 1.74%, and a one-year term.
Since March this year, the Yangtze River Delta region, the most industrially developed city in China, Shanghai, Jiangsu Province and Zhejiang Province has broken out. In Shanghai, China’s largest commercial and financial center, most areas have been under lockdown for more than 50 days.
The daily salary of nucleic acid testers in the stock market involving testing and other sectors has risen to 1,000 yuan
In all epidemic prevention and control links, nucleic acid testing (and rapid antigen testing) has always been the focus of huge interests behind it.
According to a May 10 report by Soochow Securities, China’s annual spending will reach 1.45 trillion yuan (about 205.05 billion U.S. dollars) just by normalizing testing.
The CCP authorities have recently normalized nucleic acid testing. 17 major cities such as Beijing, Shanghai, and Guangzhou require citizens to carry a 48-hour or 72-hour nucleic acid test certificate in public places. Beijing, where the epidemic broke out recently, conducted nucleic acid tests for all staff in 12 districts for three consecutive days from May 13 to 15. This is the second time since the outbreak of a new round of epidemics.
In a live broadcast of investment advisors on the Chinese portal Sina.com on May 16, reports from Haitong Securities and Yingtou revealed the reasons for the daily limit in sectors such as virus testing—the authorities required the establishment of 15-minute walk “sampling circles” in major cities as Part of the normalization of nucleic acid testing.
According to the Shanghai Securities Industry Weekly Report on May 9, even if only the urban population is considered, 750,000 new testing points and more than 1 million nucleic acid testing personnel still need to be added nationwide.
The Shanghai Municipal Health Commission said on May 15 that the city has about 38,000 sampling personnel, and the maximum detection capacity in a single day has increased from 1.028 million tubes before the current round of the epidemic to 8.5 million tubes. From March 28, when Shanghai was closed, to May 14, Shanghai has screened a total of 430 million people. Based on the resident population of 25 million, an average of 17.2 nucleic acid tests were performed per person, and each person was tested on average every three days.
At present, Hangzhou, Shenzhen and other cities are also expanding the qualifications of nucleic acid sampling personnel from the original limited to doctors and nurses to other people with local health-related professional and technical professional qualifications.
China News Weekly, the official media of the Communist Party of China, reported on May 14 that nucleic acid testing companies are recruiting a large number of qualified nucleic acid testing personnel. 45,000 USD); according to the 2020 urban employment data from the National Bureau of Statistics of China, such high salaries can only be achieved in the IT industry in Shanghai, Beijing and Zhejiang provinces.
Lai Jianping, a master of international law from China University of Political Science and Law, told The Epoch Times that the normalization of nucleic acid testing is a huge chain of interests. In a recording of a private party leaked in February this year, Huang Wansheng, a scholar who returned to China from the United States to lead the CCP’s “scientific epidemic prevention” revealed that behind the CCP’s zero-epidemic prevention, there is a huge chain of interests of the CCP’s elites, only nucleic acid testing. It made a huge profit of 670 billion yuan (about 99.34 billion US dollars).
Normalization of permanent shelters and health stations
In addition, Ma Xiaowei, director of the National Health Commission of the Communist Party of China, published an article on the official Chinese media on May 16, saying that it is necessary to plan ahead to prepare permanent makeshift hospitals and centralized isolation points to ensure that they can be quickly activated in the event of an outbreak. A makeshift hospital is a temporary isolation facility.
At the same time, the so-called “health station” of the CCP is also normalizing. At present, health stations in more than ten provinces and dozens of cities in China have been completed or are under construction.
The so-called health station is said to be an isolation institution that is suitable for both normal epidemic prevention and emergency situations.
Chinese media reported on May 17 that a health station in the southeastern coastal city of Xiamen for immigrants will be built by Chinese real estate giant Vanke Group with a total investment of about 2.2 billion yuan (about 330 million US dollars). After the completion of the nine buildings, there will be 6,001 an isolated room.
The epidemic prevention bonds of Shanghai Real Estate Group and Wenzhou Modern Service Industry Development Group also involve construction projects for epidemic prevention and isolation housing.
In addition to testing and isolation, a number of vaccine pharmaceutical companies performed well in the last fiscal year. Among them, Sinovac, one of the largest vaccine manufacturers in China, according to the Chinese media “Daily Economic News”, has an annual net profit of more than 53 billion yuan (about 7.86 billion US dollars) attributable to shareholders of listed companies; another vaccine The manufacturer CanSinoBio saw its operating income soar by 170 times last year, thus turning losses into profits year-on-year; Zhifei Bio’s net profit attributable to shareholders of listed companies increased by 2 times year-on-year last year.
Responsible editor: Sun Yun#